All In Biotech

Drug Trial Radar · NCT00953147

A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older

A 6-Month Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of Once Daily Ciclesonide HFA Nasal Aerosol (80 and 160 μg) in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older

Last checked: Nov 19, 2026Latest source record: Jun 13, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,110 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,110

Actual

Start

Aug 2009

Primary completion

Jan 2010

Study completion May 2010

Sponsor

Lead sponsor
Sumitomo Pharma America, Inc.Industry
Sponsor type
Industry
First posted
Aug 6, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 6-month multi-center, randomized, double-blind, placebo-controlled, parallel group, efficacy and safety study of ciclesonide HFA nasal aerosol administered once-daily to male and female subjects 12 years or older diagnosed with perennial allergic rhinitis (PAR).

Conditions

  • Allergic Rhinitis
  • Perennial Allergic Rhinitis

Interventions

  • Ciclesonide HFA 80 mcgDrug

    Ciclesonide HFA Nasal Aerosol 80 mcg once daily for 6 months in the treatment of Perennial Allergic Rhinitis (PAR) in subjects 12 years and older.

  • Ciclesonide HFA 160 mcgDrug

    Ciclesonide HFA Nasal Aerosol 160 mcg once daily for 6 months in the treatment of Perennial Allergic Rhinitis (PAR) in subjects 12 years and older.

  • PlaceboDrug

    Placebo HFA Nasal Aerosol once daily for 6 months in the treatment of Perennial Allergic Rhinitis (PAR) in subjects 12 years and older.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Daily Subject-reported AM and PM Reflective TNSS (rTNSS) Averaged Over the First 6 Weeks of Double-blind TreatmentTime frame: Weeks 0-6

Locations

45 sites in 1 country. Site status is shown where the registry gives one.

  • Asthma and Allergy Specialists Medical Group

    Huntington Beach, California

  • California Allergy and Asthma Medical Group

    Los Angeles, California

  • Southern California Research

    Mission Viejo, California

  • CHOC PSF, AMC, Division of Allergy Asthma & Immunology

    Orange, California

  • California Allerga and Asthma Medical Group

    Palmdale, California

  • Allergy Associates Medical Group

    San Diego, California

  • Allergy and Asthma Medical Group and Research Center

    San Diego, California

  • Bensch Research Associates

    Stockton, California

  • Asthma and Allergy Associates, P.C.

    Colorado Springs, Colorado

  • Storms Clinical Research Institute

    Colorado Springs, Colorado

  • Colorado Allergy and Asthma Centers

    Denver, Colorado

  • Clinical Research Atlanta

    Atlanta, Georgia

  • DataQuest Medical Research, LLC

    Lawrenceville, Georgia

  • Allergy and Asthma Consultants, PC

    Lilburn, Georgia

  • Clinical Research Atlanta

    Stockbridge, Georgia

  • Clinical Research Center of Indiana

    Indianapolis, Indiana

  • Gordon D. Raphael, MD

    Bethesda, Maryland

  • Northeast Medical Research Associates, Inc.

    North Dartmouth, Massachusetts

  • The Clinical Research Center, LLC

    St Louis, Missouri

  • Clinical Research Group of Montana

    Bozeman, Montana

  • Princeton Center for Clinical Research

    Skillman, New Jersey

  • Allergy and Asthma Center of NC

    High Point, North Carolina

  • North Carolina Clinical Research

    Raleigh, North Carolina

  • Toledo Center for Clinical Research

    Sylvania, Ohio

  • Allergy and Asthma Research Group

    Eugene, Oregon

  • Baker Allergy, Asthma and Dermatology Research Center, LLC

    Lake Oswego, Oregon

  • Allergy Associates Research Center

    Portland, Oregon

  • Valley Clinical Research Center

    Bethlehem, Pennsylvania

  • Asthma and Allergy Research Associates

    Upland, Pennsylvania

  • Asthma, Nasal Disease and Allergy Research Center of New England

    Providence, Rhode Island

  • National Allergy, Asthma, and Urticaria

    Charleston, South Carolina

  • Allergy and Asthma Associates

    Austin, Texas

  • Sirius Clinical Research

    Austin, Texas

  • Hill Country Family Medical Center

    Boerne, Texas

  • Pharmaceutical Research and Consulting

    Dallas, Texas

  • Western Sky Medical Research

    El Paso, Texas

  • North Texas Institute for Clinical Trials

    Fort Worth, Texas

  • Allergy and Asthma Associates

    Houston, Texas

  • Kerrville Research Associates, PA

    Kerrville, Texas

  • Kerrville Research Associates

    Kerrville, Texas

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.